Sev­en years in the mak­ing, Seat­tle Ge­net­ics picks up ear­ly op­tion on Gen­mab's ADC ef­fort

Sev­en years af­ter Copen­hagen-based Gen­mab inked a col­lab­o­ra­tion deal with Seat­tle Ge­net­ics, the US biotech has de­cid­ed to opt-in on a de­vel­op­ment part­ner­ship.

The pact struck in 2010 gave Gen­mab rights to Seat­tle Ge­net­ics an­ti­body-drug con­ju­gate tech so it could work on a new ap­proach for its Hu­Max-TF an­ti­body tar­get­ing the tis­sue fac­tor anti­gen. A year lat­er they struck a deal giv­ing Seat­tle Ge­net­ics an opt-in on ti­so­tum­ab ve­dotin, now in sev­er­al Phase I/II stud­ies for sol­id tu­mors, in­clud­ing re­cur­rent cer­vi­cal can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.